Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MLH1 |
Variant | negative |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | MLH1 negative indicates a lack of expression of the MLH1 mRNA and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
MLH1 mutant MLH1 inact mut MLH1 negative |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03871959 | Phase I | Pembrolizumab + Xevinapant | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) | Completed | FRA | 0 |
NCT06509126 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE-2) | Recruiting | ITA | 0 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |
NCT06278857 | Phase II | Dostarlimab-gxly | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (SATELLITE) | Not yet recruiting | AUS | 0 |
NCT04014530 | Phase Ib/II | Pembrolizumab + PTC124 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) | Recruiting | NLD | 0 |
NCT04984733 | Phase II | Nivolumab + Temozolomide | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE) | Recruiting | GBR | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06152523 | Phase II | MEDI5752 + Monalizumab | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI) | Not yet recruiting | FRA | 0 |
NCT06529523 | Phase II | Tislelizumab | Tislelizumab in People With Colorectal Cancer | Recruiting | USA | 1 |
NCT05480306 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin | Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) | Active, not recruiting | USA | DEU | 1 |
NCT05510895 | Phase II | Binimetinib + Cetuximab + Encorafenib | Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF) | Recruiting | DEU | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT06084416 | Phase I | AMG 650 | A Study of Sovilnesib in Subjects With Ovarian Cancer | Recruiting | USA | 0 |
NCT04991948 | Phase I | Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab | Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Recruiting | USA | BEL | 0 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06107413 | Phase II | ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Recruiting | USA | ISR | 3 |
NCT03186326 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | Unknown status | FRA | 0 |
NCT03519412 | Phase II | Pembrolizumab Temozolomide Pembrolizumab + Temozolomide | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) | Active, not recruiting | ITA | 0 |
NCT04272034 | Phase I | INCB099318 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | Terminated | USA | SWE | NOR | GBR | FIN | DNK | BEL | 0 |
NCT05722886 | Phase II | Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE) | Recruiting | GBR | 0 |
NCT04817826 | Phase II | Durvalumab + Tremelimumab | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY) | Recruiting | ITA | 0 |
NCT05173987 | Phase III | Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 6 |
NCT05077800 | Phase II | Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | Recruiting | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT06243393 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Metastatic Colorectal Cancer (TROPHIT1) | Recruiting | DEU | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT05999812 | Phase II | Atezolizumab + Bevacizumab + Tretinoin | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | Recruiting | USA | 0 |
NCT04393454 | Phase II | Sirolimus | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | Terminated | USA | 0 |
NCT05615818 | Phase III | Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Recruiting | GBR | FRA | BEL | 0 |
NCT05733611 | Phase II | Atezolizumab + Bevacizumab + RP2 Atezolizumab + Bevacizumab + RP3 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Active, not recruiting | USA | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT04854434 | Phase II | Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Terminated | USA | 0 |
NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Active, not recruiting | USA | SWE | SVK | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 0 |
NCT03803553 | Phase III | Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Recruiting | USA | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT06567782 | Phase II | Capecitabine + Dostarlimab-gxly + Oxaliplatin Capecitabine + Oxaliplatin | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (AZUR-4) | Not yet recruiting | GBR | ESP | BEL | 0 |
NCT05272709 | Phase Ib/II | TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | GBR | 0 |
NCT06225843 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Sotevtamab | Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003) | Recruiting | CAN | 0 |
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05118724 | Phase II | Atezolizumab | Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) | Recruiting | DEU | 0 |
NCT05419817 | Phase II | Pembrolizumab + Sitravatinib | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | Withdrawn | 0 | |
NCT05672095 | Phase Ib/II | Niraparib | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | Not yet recruiting | USA | 0 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Recruiting | DEU | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05732389 | Phase II | Ipilimumab + Nivolumab | Immunotherapy in Patients With Early dMMR Rectal Cancer (RESET-R) | Recruiting | DNK | 0 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT04729322 | Phase I | Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | Active, not recruiting | USA | 0 |
NCT05984602 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Tislelizumab | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT05961709 | Phase II | Cemiplimab | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Recruiting | USA | 0 |
NCT05870800 | Phase II | Atezolizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin | Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer | Not yet recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT05263492 | Phase II | Lenvatinib + Pembrolizumab | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT05843188 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hydroxychloroquine + Irinotecan + Leucovorin | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | Recruiting | CAN | 0 |
NCT05141721 | Phase II | Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05836584 | Phase II | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | Recruiting | USA | 0 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05609370 | Phase Ib/II | Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | AUS | 2 |
NCT06300463 | Phase II | Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Recruiting | USA | 0 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT06411600 | Phase II | Bevacizumab + Cetuximab + Encorafenib Bevacizumab | Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE) | Recruiting | ESP | 0 |
NCT05909423 | Phase II | Influenza vaccine + Pembrolizumab | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer (FLU-IMMUNE) | Not yet recruiting | DNK | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Completed | USA | 0 |
NCT05504252 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Nivolumab | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2) | Recruiting | NOR | 0 |
NCT06180733 | Phase II | Pembrolizumab | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) | Recruiting | NLD | 0 |
NCT05088889 | Phase I | Ipilimumab + Nivolumab | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | Recruiting | ISR | 0 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Recruiting | USA | 0 |
NCT06395090 | Phase Ib/II | MK-7684A MK-4280 + Pembrolizumab Pembrolizumab + Vibostolimab MK-4280A | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | Recruiting | USA | 1 |
NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT05382741 | Phase II | Durvalumab + Regorafenib | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA) | Recruiting | ITA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT06522919 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Pembrolizumab | Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax) | Not yet recruiting | ITA | 0 |
NCT05205330 | Phase Ib/II | Balstilimab + CR6086 | CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers | Recruiting | ITA | 0 |
NCT04659382 | Phase II | Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) | Recruiting | FRA | 0 |
NCT06625515 | Phase I | ATX-559 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients with Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | Recruiting | USA | 0 |
NCT05417386 | Phase I | Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFIRINOX + NIS793 in Pancreatic Cancer | Terminated | USA | 0 |
NCT04729959 | Phase II | Atezolizumab + Tocilizumab | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04019964 | Phase II | Nivolumab | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | Recruiting | USA | 0 |
NCT06575725 | Phase II | Balstilimab + Botensilimab + Regorafenib Balstilimab + Botensilimab | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | Not yet recruiting | 0 | |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT05310643 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) | Recruiting | FRA | 0 |
NCT03505320 | Phase II | Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Pembrolizumab + Zolbetuximab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Zolbetuximab Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (ILUSTRO) | Active, not recruiting | USA | ITA | FRA | 3 |
NCT05178576 | Phase II | XOMA 052 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | Withdrawn | USA | 0 |
NCT04730544 | Phase II | Ipilimumab + Nivolumab | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) | Recruiting | FRA | 0 |
NCT06065462 | Phase Ib/II | Dostarlimab-gxly + LB-100 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | Recruiting | USA | 0 |
NCT05167409 | Phase II | Cetuximab + Evorpacept + Pembrolizumab | A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05064059 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Active, not recruiting | USA | TUR | NOR | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 9 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05909995 | Phase I | INCB099280 + Ipilimumab | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT06366347 | Phase II | Pembrolizumab Abemaciclib + Letrozole | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | Recruiting | USA | 0 |
NCT06116136 | Phase Ib/II | Pembrolizumab + S095029 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | Recruiting | USA | ITA | HUN | FRA | ESP | DNK | BEL | AUT | AUS | 0 |
NCT04964375 | Phase I | ABSK043 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor | Unknown status | AUS | 0 |
NCT05322590 | Phase Ib/II | BXQ-350 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST) | Recruiting | USA | 0 |
NCT04906382 | Phase I | Carboplatin + Paclitaxel + Tislelizumab | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Terminated | USA | 0 |
NCT06365970 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers | Not yet recruiting | USA | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06046274 | Phase II | GEN1046 + Pembrolizumab | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | Withdrawn | USA | ITA | ESP | DNK | BEL | 1 |
NCT04935359 | Phase III | Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Completed | USA | TUR | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | 6 |
NCT04166721 | Phase Ib/II | Atezolizumab + DKN-01 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | Active, not recruiting | GBR | 0 |
NCT05328908 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | Active, not recruiting | USA | SWE | POL | NLD | ITA | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT05672524 | Phase II | Trastuzumab + Tucatinib | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | Recruiting | USA | 0 |
NCT04963283 | Phase II | Cabozantinib + Nivolumab | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05177133 | Phase II | Capecitabine + Oxaliplatin + Retifanlimab | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (AuspiCiOus) | Recruiting | NLD | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT05308446 | Phase II | Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Active, not recruiting | USA | 1 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Active, not recruiting | CAN | 0 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Active, not recruiting | FRA | 0 |
NCT05710406 | Phase II | Cetuximab + Encorafenib | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | Recruiting | USA | 0 |
NCT05112601 | Phase II | Ipilimumab + Nivolumab Nivolumab | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Recruiting | USA | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04751370 | Phase II | Ipilimumab + Nivolumab | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | Suspended | USA | 0 |
NCT05672316 | Phase Ib/II | Balstilimab + Botensilimab + Regorafenib | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | Active, not recruiting | USA | 0 |
NCT03724071 | Phase Ib/II | Flucytosine + TG6002 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Terminated | FRA | ESP | BEL | 0 |
NCT04800627 | Phase Ib/II | MLN4924 + Pembrolizumab | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | Terminated | USA | 0 |
NCT04006262 | Phase II | Ipilimumab + Nivolumab | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA) | Recruiting | FRA | 0 |
NCT06346197 | Phase III | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Balstilimab + Botensilimab | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME) | Not yet recruiting | FRA | 0 |
NCT03506997 | Phase II | Pembrolizumab | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) | Recruiting | GBR | 0 |
NCT06006923 | Phase II | Pembrolizumab Pembrolizumab + Regorafenib | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Recruiting | USA | 0 |
NCT04197219 | Phase II | Axitinib + Pembrolizumab | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Withdrawn | 0 | |
NCT05584670 | Phase Ib/II | SAR445877 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | NLD | ISR | ESP | 0 |
NCT04262687 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin + Pembrolizumab | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) | Recruiting | FRA | 0 |
NCT06410534 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT02912572 | Phase II | Avelumab + Talazoparib Avelumab Avelumab + Axitinib | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04717154 | Phase II | Ipilimumab + Nivolumab | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) | Active, not recruiting | NLD | 0 |
NCT04952753 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 5 |
NCT06004245 | Phase I | RO7589831 | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | DNK | CAN | BEL | 0 |
NCT06059495 | Phase II | Dostarlimab-gxly | Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI) | Recruiting | FRA | 0 |
NCT02998567 | Phase I | Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) | Recruiting | GBR | 0 |
NCT05427487 | Phase I | IVX037 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT05425940 | Phase III | Atezolizumab + XL092 Regorafenib | Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | Active, not recruiting | USA | POL | NZL | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT05608044 | Phase II | Balstilimab + Botensilimab Botensilimab | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Active, not recruiting | USA | ITA | FRA | ESP | BRA | BEL | 2 |
NCT05854498 | Phase II | Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |
NCT05005728 | Phase II | XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05197322 | Phase II | Pembrolizumab | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) | Recruiting | GBR | 0 |
NCT05723562 | Phase II | Dostarlimab-gxly | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT06646445 | Phase II | Pembrolizumab Capecitabine + Oxaliplatin Capecitabine Fluorouracil Fluorouracil + Oxaliplatin | Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial (PREMICES) | Not yet recruiting | FRA | 0 |
NCT05593328 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | Active, not recruiting | USA | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT06106308 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Recruiting | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Recruiting | USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS | 2 |
NCT06634875 | Phase II | Isunakinra | Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) | Not yet recruiting | USA | 0 |
NCT06205836 | Phase II | Cemiplimab Cemiplimab + Fianlimab | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | Recruiting | USA | 0 |
NCT05838768 | Phase I | HRO761 HRO761 + Tislelizumab HRO761 + Irinotecan | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Recruiting | USA | SWE | NOR | ITA | ISR | FRA | ESP | DEU | BEL | 5 |